Skip to NavigationSkip to content

atopic dermatitis

Sanofi's Dupixent chalks up CHMP recommendation for paediatric severe atopic dermatitis

Sanofi’s interleukin-4 and -13 inhibitor Dupixent (dupilumab) has been given the recommendation of the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) in the treatment of severe atopic dermatitis, when combined with topical corticosteroids (TCS).

The backing is specific to patients between the ages of six and 11 who are eligible for systemic therapy.

Sanofi's Dupixent scores Chinese approval in moderate to severe atopic dermatitis

China’s National Medical Products Administration (NMPA) has moved to approve a 300mg pre-filled pen formulation of Sanofi and Regeneron’s Dupixent (dupilumab), it has emerged, for the treatment of moderate to severe atopic dermatitis (AD).

The Chinese regulator awarded approval specifically to adult patients for whom topical prescription therapies are inadvisable or ineffective, following an accelerated review after identifying the therapy as one urgently needed in clinical practice.

Incyte's ruxolitinib cream formulations look strong in Phase 3 atopic dermatitis

Incyte has lifted the curtain on promising new Phase 3 data for its 0.75% and 1.5% twice daily cream formulations of ruxolitinib in the treatment of mild-to-moderate atopic dermatitis.

The findings from two studies were presented at the Revolutionizing Atopic Dermatitis Virtual Symposium on Sunday; both met their main goal, with a greater proportion of ruxolitinib patients achieving an Investigator’s Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) with at least a two-point improvement from baseline after eight weeks of treatment.

Sanofi and Regeneron's Dupixent combo impresses in paediatric atopic dermatitis

Sanofi and Regeneron have unveiled new Phase 3 data for their IL-4 and IL-13 inhibitor Dupixent (dupilumab), showing strong results in children aged 6-11 years with uncontrolled severe atopic dermatitis when combined with standard-of-care topical corticosteroids (TCS).

Morphosys, Novartis and Galaagos shut down development of atopic dermatitis candidate

The trio of Galapagos, MorphoSys and Novartis Pharma has revealed that all further development of its MOR106 drug candidate for the treatment of atopic dermatitis is to be terminated.

The decision was reached by all three parties after an interim analysis discovered that the candidate was unlikely to meet the study’s primary endpoint of percentage change in the eczema area and severity index (EASI) score.

However, the company pointed out that while the therapy’s efficacy was in question, its safety profile was not.

Pfizer reveals strong Phase 3 data for abrocitinib in atopic dermatitis

Pfizer confirmed over the weekend that its oral Janus kinase 1 (JAK1) inhibitor abrocitinib met all of its co-primary and key secondary endpoints in a 12-week, Phase 3 study investigating its efficacy in the treatment of moderate to severe atopic dermatitis (AD) in patients aged 12 and older.

The findings revealed that 43.8% and 23.7% of patients achieved an Investigator Global Assessment (IGA) score of clear (0) or almost clear (1) skin with 200mg and 100mg of abrocitinib respectively compared to placebo – one of the trial’s co-primary endpoints.

Sanofi's Dupixent improves skin clearance in paediatric atopic dermatitis

As the therapy secured approval in Europe for treatment of adolescent patients with moderate-to-severe atopic dermatitis, Sanofi has revealed new Phase 3 data for Dupixent (dupilumab) in the treatment of severe atopic dermatitis in paediatric patients aged between six and 11 years old.

When used in combination with standard-of-care topical corticosteroids (TCS), 33% of patients receiving Dupixent every four weeks and 30% receiving it every two weeks achieved clear or almost clear skin with an Investigator's Global Assessment (IGA) score of 0 or 1, compared to 11% with placebo.

Pfizer's abrocitinib smashes primary and secondary endpoints at Phase 3 in atopic dermatitis

Pfizer has lifted the curtain on new Phase 3 data for its Janus kinase 1 (JAK1) inhibitor abrocitinib, revealing that the therapy met all of its co-primary and secondary endpoints in the treatment of moderate to severe atopic dermatitis (AD) in patients aged 12 and older.

The trial examined the safety and efficacy of both 100mg or 200mg once-daily doses of the drug.

Lilly's Olumiant impresses in twin Phase 3 atopic dermatitis trials

Eli Lilly has unveiled new Phase 3 data from two studies into the oral Janus kinase (JAK) inhibitor Olumiant (baricitinib). The company and its partner Incyte announced that the drug had met its primary endpoint as a monotherapy in the treatment of adult patients with moderate to severe atopic dermatitis (AD).

Specifically, the pair revealed that a “statistically significant” proportion of patients treated with the therapy achieved clear or almost clear skin after 16 weeks compared to placebo, as measured according to the Investigator's Global Assessment for AD (IGA).

Atopic dermatitis market set to almost triple in value over next 10 years

The atopic dermatitis (eczema) market is expected to reach $18.3 billion by 2027, according to analytics firm GlobalData.

The market is expected to grow from $6.4 billion in 2017 to a value of $18.3 billion in 2027 across seven major markets at a compound annual growth rate of 11.1%, as the drive to meet high levels of unmet need fuels growth. The seven major markets include the US, France, Germany, Italy, Spain, the UK, and Japan.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches